Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Decreased pulse rate01:14

Decreased pulse rate

Bradycardia is a medical condition in which the heart rate is slower than normal. It occurs when the heart's natural pacemaker, the sinus node, generates slower electrical impulses than the standard rhythm. In adults, bradycardia is diagnosed when the pulse rate falls below 60 beats per minute, indicating a deviation from the normal heart rate range.
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with bradycardia...
Pulse rhythm01:30

Pulse rhythm

Pulse rhythm refers to the pattern of pulsations within specific intervals, offering valuable insights into the regularity or irregularity of the heart's beats as observed through the pattern of pulsation within specific intervals. A regular pulse exhibits a consistent heart rate with uniform waveforms and pulsation force, variations of which can be classified as normal, weak, or bounding.
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac muscle...
Regulation of Heart Rates01:31

Regulation of Heart Rates

The regulation of heart rate is a complex process controlled by the autonomic nervous system (ANS), hormonal influences, and intrinsic cardiac mechanisms. The ANS has two main components: the sympathetic nervous system (SNS) and the parasympathetic nervous system (PNS).
The SNS increases heart rate through the release of norepinephrine and epinephrine, which act on beta-1 adrenergic receptors in the heart. This action increases the rate of depolarization in the sinoatrial (SA) node, the heart's...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Ceasefire Declared, but Ethiopian Health Systems Remain in Critical Condition After Civil War.

JAMA·2023
Same author

Substance Use, Mental Health Challenges Widespread in 2021.

JAMA·2023
Same author

Gene Edited Tumor Cells Kill and Prevent Cancer in Mice.

JAMA·2023
Same author

Letters to Clinicians May Promote Better-Informed Opioid Prescribing.

JAMA·2023
Same author

AAP Recommends Immediate, Intensive Treatment for Child Obesity.

JAMA·2023
Same author

Sickle Cell Disease Gene Therapy Trial Paused.

JAMA·2023

関連する実験動画

Updated: Jul 9, 2026

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

13.6K

心臓 の ペース を 短期間 維持 する"スマート"な ペースメーカー の 設計 を 解消 する

Howard D Larkin

    JAMA
    |July 12, 2022
    PubMed
    まとめ

    No abstract available in PubMed .

    さらに関連する動画

    Translational Rabbit Model of Chronic Cardiac Pacing
    06:14

    Translational Rabbit Model of Chronic Cardiac Pacing

    Published on: January 6, 2023

    2.7K
    Bidirectional Electrical and Optoelectronic Interfaces in Healthy and Ischemic Ex Vivo Rat Hearts
    08:40

    Bidirectional Electrical and Optoelectronic Interfaces in Healthy and Ischemic Ex Vivo Rat Hearts

    Published on: July 18, 2025

    253

    関連する実験動画

    Last Updated: Jul 9, 2026

    Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
    10:08

    Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

    Published on: February 17, 2018

    13.6K
    Translational Rabbit Model of Chronic Cardiac Pacing
    06:14

    Translational Rabbit Model of Chronic Cardiac Pacing

    Published on: January 6, 2023

    2.7K
    Bidirectional Electrical and Optoelectronic Interfaces in Healthy and Ischemic Ex Vivo Rat Hearts
    08:40

    Bidirectional Electrical and Optoelectronic Interfaces in Healthy and Ischemic Ex Vivo Rat Hearts

    Published on: July 18, 2025

    253